No Data
No Data
Express News | Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With Nab-Sirolimus At Society Of Gynecologic Oncology
Aadi Bioscience Presents New Subgroup Analysis of Patients With Advanced Malignant PEComa of Gynecologic Origin Treated With Nab-Sirolimus at Society of Gynecologic Oncology (SGO)
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers...
Express News | Aadi Bioscience Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results
Earnings Call Summary | Aadi Biosciences(AADI.US) Q4 2023 Earnings Conference
The following is a summary of the Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript:Financial Performance:Aadi Bioscience reported impressive sales growth with full-year sales for FYARRO h
Aadi Bioscience Cash Runway Extends to 4Q 2025 >AADI
Aadi Bioscience Cash Runway Extends to 4Q 2025 >AADI
Express News | Aadi Bioscience's Cash, Cash Equivalents And Short-term Investments As Of December 31, 2023, Is Expected To Fund Operations Into Q4 2025 Based On Current Plans
No Data